Preparation and in vitro evaluation of pyridostigmine bromide microparticles

被引:18
作者
Hegazy, N [1 ]
Demirel, M [1 ]
Yazan, Y [1 ]
机构
[1] Anadolu Univ, Fac Pharm, Dept Pharmaceut Technol, TR-26470 Eskisehir, Turkey
关键词
pyridostigmine bromide; microparticles; spray-drying; release;
D O I
10.1016/S0378-5173(02)00146-1
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Pyridostigmine bromide (PB) is an anticholinesterase agent whose aqueous solubility is high and which has a short elimination half-life. Its dosage rate in the treatment of myastenia gravis is frequent due to the short half-life and it exhibits side effects. Microparticles designed to deliver a pharmaceutical active ingredient efficiently at the minimum dose and also to enhance stability, reduce side effects and modify drug release were prepared in this study using an acrylic polymer (Eudragit) as the vehicle by the spray-drying technique. The drug was either dissolved or dispersed in the polymeric solution and following the preparation of microparticles using different ratios of ingredients, characterization studies including the determination of shape, particle size distribution, amount loaded, release and stability of PB were performed. The results obtained were compared to those of pure PB. Drug release from microparticles could be modified and was found to depend on the shapes of the microparticles. In vitro evaluation results indicate that the frequent dosage and side effects of pure PB may be reduced with the formulation of microparticles. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码:171 / 174
页数:4
相关论文
共 12 条
[1]
Recombinant human erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics [J].
Bittner, B ;
Morlock, M ;
Koll, H ;
Winter, G ;
Kissel, T .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1998, 45 (03) :295-305
[2]
NEUROMUSCULAR FUNCTION AND PLASMA DRUG LEVELS IN PYRIDOSTIGMINE TREATMENT OF MYASTHENIA-GRAVIS [J].
BREYERPFAFF, U ;
SCHMEZER, A ;
MAIER, U ;
BRINKMANN, A ;
SCHUMM, F .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (06) :502-506
[3]
SPRAY-DRIED POLYLACTIDE MICROSPHERE PREPARATION - INFLUENCE OF THE TECHNOLOGICAL PARAMETERS [J].
CONTE, U ;
CONTI, B ;
GIUNCHEDI, P ;
MAGGI, L .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1994, 20 (03) :235-258
[4]
TESTING OF IN-VITRO DISSOLUTION BEHAVIOR OF MICROPARTICULATE DRUG-DELIVERY SYSTEMS [J].
CONTI, B ;
GENTA, I ;
GIUNCHEDI, P ;
MODENA, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1995, 21 (10) :1223-1233
[5]
GIUNCHEDI P, 1995, STP PHARMA SCI, V5, P276
[6]
Guo X, 1997, STP PHARMA SCI, V7, P521
[7]
PHARMACOLOGICAL AND TOXICOLOGICAL EVALUATION OF ORALLY-ADMINISTERED PYRIDOSTIGMINE IN DOGS [J].
KLUWE, WM ;
PAGE, JG ;
TOFT, JD ;
RIDDER, WE ;
CHUNG, H .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1990, 14 (01) :40-53
[8]
Effects of pyridostigmine on acetylcholinesterase in different muscles of the mouse [J].
Lintern, MC ;
Smith, ME ;
Ferry, CB .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1997, 16 (01) :18-24
[9]
Pignatello R, 1997, STP PHARMA SCI, V7, P148
[10]
DEVELOPMENT OF BIODEGRADABLE MICROSPHERES AND NANOSPHERES FOR THE CONTROLLED-RELEASE OF CYCLOSPORINE-A [J].
SANCHEZ, A ;
VILAJATO, JL ;
ALONSO, MJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 99 (2-3) :263-273